Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02704364 · ClinicalTrials.gov registry record · Phase 2
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2 study of Primary Sclerosing Cholangitis, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 20
- Study locations
NCT02704364: Completed Phase 2 study of Primary Sclerosing Cholangitis, sponsored by NGM Biopharmaceuticals.
NCT02704364 is a Phase 2 study of Primary Sclerosing Cholangitis that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 62 participants, below the 550-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02704364, a Phase 2 study of Primary Sclerosing Cholangitis, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.
Primary Outcome
Blood samples were collected to assess changes in alkaline phosphatase levels.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL NGM282
Study Locations (20)
Texas
- NGM Clinical Study Site 113 - Dallas
- NGM Clinical Study Site 117 - Dallas
- NGM Clinical Study Site 119 - Houston
- NGM Clinical Study Site 125 - Southlake
California
- NGM Clinical Study Site 118 - Sacramento
- NGM Clinical Study Site 112 - San Clemente
- NGM Clinical Study Site 127 - San Francisco
Florida
- NGM Clinical Study Site 110 - Gainesville
- NGM Clinical Study Site 124 - Lakewood Rch
- NGM Clinical Study Site 105 - Miami
Missouri
- NGM Clinical Study Site 102 - Kansas City
- NGM Clinical Study Site 107 - St Louis
Colorado
- NGM Clinical Study Site 106 - Aurora
District of Columbia
- NGM Clinical Study Site 115 - Washington D.C.
Indiana
- NGM Clinical Study Site 109 - Indianapolis
Michigan
- NGM Clinical Study Site 104 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02704364 record still lists
NCT02704364 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 550-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02704364 names 20 study sites across 12 states, led by Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02704364 about?
NCT02704364 is a clinical study titled "A Study of NGM282 in Patients With Primary Sclerosing Cholangitis". The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.
What is the current status of trial NCT02704364?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2016-03. Estimated completion is 2017-06.
What conditions does trial NCT02704364 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis.
What interventions are being tested in trial NCT02704364?
The interventions under investigation include: Placebo (OTHER), NGM282 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02704364?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02704364 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02704364's enrollment target sits among peer trials
62 14th of 23 higher than 10 of 23 other Primary Sclerosing Cholangitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Sclerosing Cholangitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
RECRUITING · Phase 2
-
Detoxification of the Liver In PSC (Dolphin)
RECRUITING · Phase 2
-
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
ACTIVE NOT RECRUITING · Phase 2
-
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia